Preclinical pharmacology of AL-12182, a new ocular hypotensive 11-oxa prostaglandin analog

Journal of Ocular Pharmacology and Therapeutics

Volumn 22, Issue 5, 2006, Pages 291-309

  Sharif, Najam A ^a   McLaughlin, Marsha A ^a   Kelly, Curtis R ^a   Xu, Shouxi ^a   Crider, Julie Y ^a   Williams, Gary W ^a   Parker, Janet L ^b  

^a ALCON RESEARCH LTD   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXA PROSTAGLANDIN DERIVATIVE; 5,6 DIHYDRO 4,5 DIDEHYDRO 11 DEOXY 11 OXA 16 (3 CHLOROPHENOXY) OMEGA TETRANOR PROSTAGLANDIN F2ALPHA ISOPROPYL ESTER; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; AL 12182; CALCIUM ION; CLOPROSTENOL; LATANOPROST; PROSTAGLANDIN D; PROSTAGLANDIN D RECEPTOR; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN EP2 RECEPTOR; PROSTAGLANDIN EP3 RECEPTOR; PROSTAGLANDIN F RECEPTOR AGONIST; PROSTAGLANDIN IP RECEPTOR; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN TP RECEPTOR; TRAVOPROST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM MOBILIZATION; CAT; CILIARY MUSCLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; GLAUCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MIOSIS; MOUSE; NEUROTRANSMITTER RELEASE; NONHUMAN; OPHTHALMIC ARTERY; PRIMATE; PROSTAGLANDIN SYNTHESIS; PUPIL; RABBIT; RECEPTOR AFFINITY; SWINE; TRABECULAR MESHWORK;

ANIMALS; CATS; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; DRUG EVALUATION, PRECLINICAL; EYE; HUMANS; HYPEREMIA; INTRAOCULAR PRESSURE; MACACA FASCICULARIS; MICE; OCULAR HYPERTENSION; OPHTHALMIC ARTERY; PROSTAGLANDINS, SYNTHETIC; PROTEIN BINDING; RABBITS; RATS; RECEPTORS, PROSTAGLANDIN; SWINE; SWISS 3T3 CELLS; VASOCONSTRICTION;

EID: 33750724166     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.22.291     Document Type: Article

References (51)

1. Coleman, R.A., Smith, W.L. and Narumiya, S., VIII. International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46:205-229, 1994.
2. Narumiya, S., Hirata, M., Namba, T., et al. Structure and function of prostanoid receptors. J. Lipid Mediat. 6:155-161, 1993.
3. 2, and their esters in glaucomatous monkey eyes. Invest. Ophthalmol. Vis. Sci. 31:2466-2470, 1990.
4. Bito, L.Z. Prostaglandins: A new approach to glaucoma management with a new intriguing side-effect. Surv. Ophthalmol. 41(Suppl):S1-S14, 1997.
5. Hellberg, M.R., McLaughlin, M.A., Sharif, N.A., et al. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv. Ophthalmol. 47(suppl 1):S13-S33, 2002.
6. Abdel-Latif, A.A. Phosphoinositide and arachidonic acid signalling systems in the mammalian iris. Prog. Ret. Eye Res. 14:75-107, 1995.
7. Goh, Y. and Kishino, J. Pharmacological characterization of prostaglandin-related ocular hypotensive agents. Jpn. J. Ophthalmol. 38:236-245, 1994.
8. Chegini, N., Lei, Z.M., Rao, Ch.V., et al. Cellular distribution and cycle phase dependency of gonadotropin and eicosanoid binding sites in bovine corpora lutea. Biol. Reprod. 45:506-513, 1991.
9. 3 and FP-receptor binding sites in bovine corpus luteum: Characterization and correlation with functional data. J. Pharmacol. Exp. Ther. 286:1094-1102, 1998.
10. Senior, J., Marshall, K., Sangha, R., et al. In vitro characterization of prostanoid receptors on human myometrium at term pregnancy. Br. J. Pharmacol. 108:501-506, 1993.
11. Chen, J., Champa-Rodriguez, M.L., and Woodward, D.F. Identification of a prostanoid FP-receptor population producing endothelium-dependent vasorelaxation in the rabbit jugular vein. Br. J. Pharmacol. 116:3035-3041, 1995.
12. Griffin, B.W., Williams, G.W., Crider, J.Y., et al. FP prostaglandin receptors mediating inositol phosphate generation and calcium mobilization in Swiss 3T3 cells: A pharmacological study. J. Pharmacol. Exp. Ther. 281:845-854, 1997.
13. Griffin, B.W., Magnino, P.E., Pang, I.-H., et al. Pharmacological characterization of an FP prostaglandin receptor on rat vascular smooth muscle cells (A7r5) coupled to phosphoinositide turnover and intracellular calcium mobilization. J. Pharmacol. Exp. Ther. 286:411-418, 1998.
14. 2α receptor messenger RNA and protein in the cynomolgus monkey eye. Invest. Ophthalmol. Vis. Sci. 37:716-726, 1996.
15. 4, and FP-receptors in human ciliary epithelial and ciliary muscle cells. Biochem. Pharmacol 53:1249-1255, 1997.
16. Schlotzer-Schrehardt, U., Zenkel, M., and Nusing, R. Expression and localization of FP and EP prostanois receptor subtypes in human ocular tissues. Invest. Ophthalmol. Vis. Sci. 43:1475-1487, 2002.
17. 2 receptor is the predominant prostanoid receptor in the human ciliary muscle. Br. J. Ophthalmol. 77:110-114, 1993.
18. Davis, T.L., and Sharif, N.A. Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology. J. Ocul. Pharmacol. Ther. 15:323-336, 1999.
19. 3H]9-β-(+)fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin, to study pharmacology and autoradiographic localization of FP-receptors. J. Pharm. Pharmacol. 51:685-694, 1999.
20. 2+ mobilization, and MAP kinase activation. J. Ocul. Pharmacol. Ther. 19:437-455, 2003.
21. Sharif, N.A., Kelly, C.R., and Crider, J.Y. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest. Ophthalmol. Vis. Res. 44:715-721, 2003.
22. Sharif, N.A., Kelly, C.R., Crider, J.Y., et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG-receptor subtype binding affinities and selectivities, and agonist potencies at FP- and other PG-receptors in cultured cells. J. Ocul. Pharmacol. Ther. 19:501-515, 2003.
23. 2α (FP) receptor. J. Pharmacol. Exp. Ther. 290:1278-1284, 1999.
24. 2α. Arch. Ophthalmol. 105:1112-1116, 1987.
25. 2α increases uveoscleral outflow in the cynomolgus monkey. Exp. Eye Res. 49:389-402, 1989.
26. 2α-1-isopropylester in the cynomolgus monkey. Exp. Eye Res. 48:707-716, 1989.
27. 2α in the human eye. Graefe's Arch. Clin. Exp. Ophthalmol. 222:139-141, 1985.
28. 2α analogue. Adv. Prost. Thromb. Leuk. Res. 23:513-518, 1995.
29. Aim, A. Prostaglandin derivates as ocular hypotensive agents. Prog. Ret. Eye Res. 17:291-312, 1998.
30. Selliah, R.D., Hellberg, M.R., Sharif, N.A., et al. AL-12182, a novel 11-oxa prostaglandin analog with topical ocular hypotensive activity in the monkey. Bioorg. Med. Chem. Lett. 14:4525-4528, 2004
31. Sharif, N.A., Crider, J.Y., Xu, S.X., et al. Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: Focus on DP-class prostanoids. J. Pharmacol. Exp. Ther. 293:321-328, 2000.
32. 2-, and IP-prostaglandin receptors in human ocular and other cell-types. Prost. Leuk. Essent. Fatty Acids 59:77-82, 1998.
33. Sharif, N.A., Senchyna, M., and Xu, S.X. Pharmacological and molecular biological (RT-PCR) characterization of functional TP prostanoid receptors in immortalized human nonpigmented ciliary epithelial cells. J. Ocul. Pharmacol. Ther. 18:141-162, 2002.
34. 1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J. Pharm. Pharmacol. 54:539-547, 2002.
35. 4 prostanoid receptor. Br. J. Pharmacol. 130:1919-1926, 2000.
36. Crider, J.Y., Griffin, B.W., and Sharif, N.A. Prostaglandin DP-receptors positively coupled to adenylyl cyclase in embryonic bovine tracheal (EBTr) cells: Pharmacological characterization using agonists and antagonists. Br. J. Pharmacol. 127:204-210, 1999.
37. 2 receptor in human nonpigmented ciliary epithelial cells. J. Ocul. Pharmacol. Ther. 14:293-304, 1998.
38. 2+ -mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenous mouse, rat, and cloned human FP-prostaglandin receptors. J. Pharmacol. Exp. Ther. 304:238-245, 2003.
39. Bowen, W.P., and Jerman, J. Nonlinear regression using spreadsheets. Trends Pharmacol. Sci. 16:413-417, 1995.
40. Parker J.L., Mattox, M.L., and Laughlin, H.M. Contractile responsiveness of coronary arteries from exercise-trained rats. J Appl. Physiol. 83:434-443, 1997.
41. m) in coronary and mesenteric arteries of endotoxemic animals. Shock 11:64-71, 1999.
42. Rapps J.A., Sturek, M., Jones, A.W., et al. Altered reactivity of coronary arteries distal to a chronic coronary artery occlusion. Am. J. Physiol. 273: H1879-H1887, 1997.
43. Griffin K.G., Woodman, C., Price, E., et al. Endothelium-mediated relaxation of porcine collateral-dependent arterioles is improved by exercise training. Circulation 104:1393-1398, 2001.
44. Parker, J.L., and Adams, H.R. Selective inhibition of endothelium-dependent vasodilator capacity by Escherichia coli endotoxemia. Circ. Res. 72:539-551, 1993.
45. Hackett, R.B., and McDonald, T.O. Eye irritation. In: Marzulli, F.N., and Maibach, H.I. (Eds.), Dermatotoxicology. Washington, D.C.: Hemisphere Publishing, 1991:299-306.
46. Woodward, D.F., Krauss, A.H.-P., Chen, J., et al. The pharmacology of bimatoprost (Lumigan™). Surv. Ophthalmol. 45:(Suppl. 1), S337-S345, 2001.
47. Taniguchi, T., Haque, M.S.R., Sugiyama, K., et al. Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbit. J. Ocul. Pharmacol. Ther. 12:489-498, 1996.
48. 1 prostanoid receptor. Mol. Pharmacol. 59:1446-1456, 2001.
49. Al-Zadjali, K.H., Imler, M.P., and Ohia, S.E. Inhibitory effects of prostaglandins on dopamine release from the retina. Gen. Pharmacol. 25:289-296, 1994.
50. Eglen, R.M., and Whiting, R.L. Characterization of the prostanoid receptor profile of enprostil and isomers in smooth muscle and platelets. Br. J. Pharmacol. 98:1335-1343, 1989.
51. Ohia, S.E., and Jumblatt, J.E. Prejunctional prostaglandin receptors in the human iris-ciliary body. Curr. Eye Res. 10:967-975, 1991.